The ACHIEVE-1 trial evaluated orforglipron, a novel nonpeptide, small molecule oral GLP-1, for glycemic control and weight loss in patients with type 2 diabetes.

Read Healio’s in-depth coverage of the ACHIEVE-1 trial . Enlarge

In ACHIEVE-1, 559 patients with type 2 diabetes were randomly assigned to once-daily orforglipron (Eli Lilly) 3 mg, 12 mg, 36 mg or placebo. At baseline, mean HbA1c was 8% and BMI was at least 23 kg/m2.

At 40 weeks, the researchers reported significant reductions in both HbA1c and body weight across all orforglipron groups vs. placebo.

The researchers reported that the HbA1c and weight changes in ACHIEVE-1 were similar vs. those observed in the PIONEER-1 trial of oral semaglutide (Rybelsus, Novo Nordisk) and the SUSTAIN-1 trial of injectable semaglutide (Ozemp

See Full Page